Skip to main content
Mina Lobbous, MD, Neurology, Cleveland, OH

MinaLobbousMD

Neurology Cleveland, OH

Neurooncology

Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Dr. Lobbous is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lobbous' full profile

Already have an account?

  • Office

    Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center
    9500 Euclid Avenue/CA51
    Cleveland, OH 44195
    Phone+1 216-445-1379
    Fax+1 216-444-0924

Education & Training

  • University of Alabama at Birmingham School of Public Health
    University of Alabama at Birmingham School of Public HealthMSPH, Epidemiology , 2018 - 2021
  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Neurology, 2014 - 2018
  • Ain Shams University Faculty of Medicine
    Ain Shams University Faculty of MedicineClass of 2012

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 2024 - 2025
  • MN State Medical License
    MN State Medical License 2024 - 2025
  • OH State Medical License
    OH State Medical License 2021 - 2025
  • AL State Medical License
    AL State Medical License 2016 - 2022
  • American Board of Psychiatry and Neurology Neurology
  • United Council for Neurology SubspecialtiesNeuro-Oncology

Publications & Presentations

PubMed

Journal Articles

  • An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas  
    Katie Metrock, Mina Lobbous, Bruce Korf, Expert Review of Precision Medicine and Drug Development, 7/2021

Books/Book Chapters

Abstracts/Posters

  • Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma
    Louis B. Nabors, Lawrence S. Lamb, Melissa Jo Beelen, Thriumaine Pillay, Mariska ter Haak, Samantha Youngblood, Louis Vaickus, Mina Lobbous, ASCO 2021
  • Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and cape...
    Erica Michelle Stringer-Reasor, Barbara Jane O'Brien, Ariel Topletz-Erickson, Jason B White, Mina Lobbous, Kristen Riley, Jennifer Childress, Kim LaMaster, Michelle E...., ASCO 2021
  • Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001
    Katherine B. Peters, John L. Villano, Nicholas A. Butowski, Adam Louis Cohen, Joe Sammy Mendez, Pierre Giglio, Chi Zhang, Shahzad Raza, Tresa McGranahan, Mina Lobbous,..., ASCO 2021

Other

Press Mentions

  • IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
    IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual MeetingNovember 11th, 2023
  • UAB Reports Promising Phase 1 Glioblastoma Treatment Data at ASCO
    UAB Reports Promising Phase 1 Glioblastoma Treatment Data at ASCOJune 6th, 2024
  • I’m a Top Neurologist. This Is a Common Sign of Brain Cancer That People Often Ignore
    I’m a Top Neurologist. This Is a Common Sign of Brain Cancer That People Often IgnoreJune 21st, 2024

Professional Memberships